1. Dapagliflozina en la prevención y tratamiento de la insuficiencia cardiaca
- Author
-
Juan Carlos Obaya, Vicente Pallarés, Carlos Escobar, and I. Egocheaga
- Subjects
medicine.medical_specialty ,Sympathetic nervous system ,Ejection fraction ,business.industry ,Standard treatment ,Public Health, Environmental and Occupational Health ,medicine.disease ,Cardiovascular death ,chemistry.chemical_compound ,medicine.anatomical_structure ,chemistry ,Diabetes mellitus ,Heart failure ,Vasoactive ,Internal medicine ,Cardiology ,Medicine ,Dapagliflozin ,Family Practice ,business - Abstract
To substantially reduce the risk of hospitalization and death among subjects with heart failure (HF) and reduced left ventricular ejection fraction, it is necessary to make a comprehensive approach of the different neurohormonal systems that are implied in its etiopathogenesis, including not only sympathetic nervous system, and renin-angiotensin system, but also vasoactive peptides and sodium-glucose transport protein 2. The DAPA-HF trial demonstrated that the addition of dapagliflozin to the standard treatment in HF with reduced left ventricular ejection fraction, markedly decreases the risk of cardiovascular death, HF hospitalization and overall death. In addition, dapagliflozin improves functional class and quality of life. Importantly, the prognostic benefit starts early after initiating treatment with dapagliflozin, regardless baseline therapy or the presence of diabetes. All these evidences make dapagliflozin as one of the mainstays of treatment for the management of HF with reduced left ventricular ejection fraction.
- Published
- 2021